Understanding how a vaccine protects against a lung infection called coccidioidomycosis
Official title: Mechanisms of vaccine immunity against coccidioidomycosis
Funded at University of Wisconsin-Madison · NIH-11015856 · Data updated 2026-11-12
This study is testing a new nasal vaccine to see how well it helps the immune system fight off coccidioidomycosis, a fungal infection, by focusing on special immune cells in the lungs, and it's aimed at helping people who are at risk of this infection.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | February 1, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $516,607 |
| NIH project number | 5R01AI168370-03 |
| Project ID | NIH-11015856 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of coccidioidomycosis, particularly those living in endemic areas or with compromised immune systems.
✕Less likely to help
Patients who are not at risk for coccidioidomycosis or those who have already been vaccinated against it may not benefit from this research.
What this research studies
This research investigates the immune response generated by an experimental vaccine designed to protect against coccidioidomycosis, a fungal infection. The vaccine, which is delivered intranasally, aims to stimulate specific immune cells in the lungs known as tissue-resident memory T cells. By studying how lung epithelial cells contribute to this immune response, researchers hope to uncover the mechanisms that lead to long-lasting protection. The study involves innovative techniques, including the use of transgenic mice and human lung cell cultures, to translate findings from animal models to potential human applications.
Why it matters
Potential benefit: If successful, this research could lead to the development of an effective vaccine that provides long-term immunity against coccidioidomycosis.
How similar studies have gone: Other research has shown promise in using similar vaccine approaches to stimulate immune responses against various infections, indicating potential for success in this area.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: Klein, Bruce Steven — University of Wisconsin-Madison
- Study coordinator: Klein, Bruce Steven
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.